Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
125.63
-1.58 (-1.25%)
Mar 25, 2025, 4:00 PM EST - Market closed
Abbott Laboratories Revenue
In the year 2024, Abbott Laboratories had annual revenue of $41.95B with 4.59% growth. Abbott Laboratories had revenue of $10.97B in the quarter ending December 31, 2024, with 7.16% growth.
Revenue (ttm)
$41.95B
Revenue Growth
+4.59%
P/S Ratio
5.21
Revenue / Employee
$367,982
Employees
114,000
Market Cap
217.87B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 41.95B | 1.84B | 4.59% |
Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
Dec 31, 2020 | 34.61B | 2.70B | 8.48% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ABT News
- 1 day ago - Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease - PRNewsWire
- 4 days ago - 2025 Dividend Kings: Strong Run Continues - Seeking Alpha
- 8 days ago - Abbott Stock Could Be On The Verge Of A Breakout - Here's What Smart Money Sees - Seeking Alpha
- 19 days ago - Strong Earnings Lift Abbott Laboratories Shares - FXEmpire
- 20 days ago - The Dividend Aristocrats Ranked By Quality Scores: March 2025 - Seeking Alpha
- 21 days ago - Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion - Business Wire
- 21 days ago - Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD - Business Wire
- 26 days ago - My Best Dividend Aristocrats For March 2025 - Seeking Alpha